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Abstract: Seventy years after its discovery, studies of the myriad properties, and potential disease associations of uromodulin
are now burgeoning. Although normative ranges for serum/plasma uromodulin concentrations were established over 30 years
ago, their external validation occurred only in very recent, larger studies. As tubular function indices, serum and urinary uromodulin
may be more sensitive indicators of kidney graft dysfunction undetected by glomerular filtration markers, or proteinuria. Moreover,
2 sizable, just published longitudinal reports revealed that lower serum uromodulin levels were associated with cardiovascular dis-
ease (CVD) outcomes, total mortality, and infectious disease deaths, in patients with known or suspected coronary heart disease.
Preliminary longitudinal studies have reported that reduced levels of plasma or serum uromodulin were linked to progression to
end-stage renal disease in chronic kidney disease patients, and graft failure in kidney transplant recipients (KTRs). Conflicting data
on the associations, or lack thereof, between lower urinary uromodulin concentrations and accelerated loss of renal function, or
renal failure, in nontransplant chronic kidney disease patients, are perhaps due, in part, to analytical limitations in determining urine
uromodulin. Potential longitudinal associations between serum and urinary uromodulin concentrations, and CVD outcomes, graft
failure, and all-cause mortality, await validation in large, diverse cohorts of chronic KTRs. Taking advantage of an efficient case-
cohort design scheme, we demonstrate how the completed FAVORITclinical trial cohort might be ideally suited to evaluate these
associations. Using available case-cohort sample data, statistical power simulations are provided to detect relative risk estimates
of 1.50 for CVD (n = 309 events), 1.56 for graft failure (n = 223 events) or 1.50 for death fromany cause (n = 320 events), comparing
values below the median, to values equal to or above the median for serum uromodulin values. Edifying data such as these would
advance our understanding of the hypothetical utility of uromodulin measurement in KTRs considerably.
(Transplantation Direct 2017;3:e219; doi: 10.1097/TXD.0000000000000737. Published online 6 October, 2017.)“The thing that hath been, it is thatwhich shall be;
and that which is done is that which shall be
done: and there is no new thing under the sun.”
[Ecclesiastes 1:9]1
In his gloss on this verse’s meaning, the great Biblical com-mentator of the Middle Ages, Shlomo Yitzchaki (“Rashi”;
d. 1105), emphasized a seeming paradox. Rashi averred it
meant that through ongoing meditation—study—one finds
“new insights.”1 Nearly 70 years after its first characteriza-
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Transplantation DIRECT ■ 2017as uromodulin, over 3 decades later,3 studies of the apparent
myriad properties, and potential disease associations of this
85 kDa glycoprotein,3 are burgeoning.4,5
Cardiovascular disease (CVD) is the leading cause of mor-
tality in kidney transplant recipients (KTRs), whereas renal
graft loss remains a major morbidity.6-9 Data from KTRs
and nontransplant populations indicate both serum and uri-
nary uromodulin, as tubular function indices, may be more
sensitive indicators of kidney graft dysfunction not detected
by glomerular filtration markers, or proteinuria, and that
uromodulin could also have anti-infectious properties.10-20
Lower serum uromodulin levels have, in addition, been asso-
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2 Transplantation DIRECT ■ 2017 www.transplantationdirect.comand infectious disease deaths, in patients with established or
suspected coronary heart disease.21,22 Preliminary longitudi-
nal studies have further suggested that reduced levels of
plasma or serum uromodulin were linked to progression to
end-stage renal disease (ESRD) in chronic kidney disease
(CKD) patients,23 and graft failure in KTRs.24 Although
there are some significant contrary data, reduced urinary
uromodulin concentrations have been associated with the de-
velopment of accelerated loss of renal function, or renal fail-
ure, in nontransplant CKD patients, and the incidence of
urinary tract infections in the elderly.25-33
Uromodulin: Descriptive Studies and Their
Consistency Across 3 Decades
Synthesized exclusively in the kidney, within the nephron’s
thick ascending limb (TAL), but also in the distal convoluted
tubule of the nephron,4,5 uromodulin is the most abundant
protein constituent of normal urine,4,5 which also reaches
the systemic circulation via basolateral TAL production.5
Normative ranges for serum/plasma uromodulin concentra-
tions were established more than 3 decades ago by radioim-
munoassay,10-12 and validated in very recent, larger studies
using ELISAs.5,15,17 Two pioneering, seminal reports pub-
lished in 198110 and 198511 by St. Bartholomew’s Hospital
(London) investigators, based on serum/plasma and urinary
radioimmunoassay determination of uromodulin, revealed
that the glycoprotein was a normal component of human se-
rum, as well as urine, whose concentrations were intimately
related to the volume of functioning renal mass. Specific find-
ings,10,11 which supported this concluding assessment, were
as follows: undetectable uromodulin concentrations in
anephric ESRD patients on maintenance hemodialysis, and
among those with minimally functioning kidneys in situ, a
significant negative correlation between serum uromodulin
concentrations, and a surrogate for residual renal function,
time (months) since initiation of hemodialysis10; a signifi-
cant decline in prenephrectomy serum uromodulin levels
on kidney donation by healthy donors free of renal disease;
conversely, a marked elevation of serum uromodulin concen-
trations in ESRD patients after successful kidney transplanta-
tion10; statistically significant correlations between 24-hour
urinary uromodulin excretion and plasma uromodulin concen-
trations in both persons with and without CKD11; and in
patients with glomerulonephritis and available renal biopsy
data, significantly higher urinary excretion of uromodulin
per milliliter of creatinine clearance, among those with com-
paratively well-preserved tubules, relative to those with ex-
tensive tubular atrophy.11
Uromodulin and Renal Function in KTRs and
Nontransplant CKD
A 1985 study of 115 KTRs by Avis et al12 provided confir-
matory evidence for the possible utility of serum uromodulin
in distinguishing what they dubbed “tubulotoxic effects.”
Their findings indicated that even when renal function (ie,
glomerular filtration estimated as 1/serum creatinine) was
comparable (unadjusted, and by analysis of covariance-
adjustment) between 63 KTRs treated with the potentially
tubulotoxic calcineurin inhibitor, cyclosporine A (CsA),
52 KTRs without calcineurin inhibitor, treated only with
azathioprine/prednisolone, and 30 healthy controls free of
CKD, the KTRs receiving CsA had disproportionately lowserum uromodulin concentrations.12 Dawnay et al13 subse-
quently reported in 1988 that 10 patients with primary bili-
ary cirrhosis on CsA therapy for a median of 26-months,
had significantly lower serum and urinary uromodulin con-
centrations, compared to non-CsA using healthy controls,
without CKD. The primary biliary cirrhosis patients, in
addition, were better differentiated from the controls by
serum uromodulin, relative to serum creatinine.13 Lastly,
McLaughlin et al14 (in 1993) reported that among 31 KTRs
undergoing allograft biopsy for presumptive acute rejection,
those who experienced ischemic tubular damage (7 episodes
of acute tubular necrosis), in the absence of histologic rejec-
tion, had significantly lower urinary uromodulin levels, com-
pared to those with biopsy-proven rejection (37 episodes).
Some 24 years later, a preliminary study of 91 kidney/
kidney-pancreas transplant recipients just reported by Steubl
et al24 suggests that determining serum uromodulin concen-
trations could have longer term prognostic value. These in-
vestigators found that lower baseline serum uromodulin
concentrations were independently associated with subse-
quent graft loss.24During amean follow-up of 3.6 ± 2.2 years
there were 13 graft losses, with 9 of 13 of the failed grafts
occurring among those with uromodulin concentrations in
the lowest quartile.24 A consistent longitudinal preliminary
study of baseline plasma uromodulin concentrations, and
ESRD development among 114 Chinese CKD patients sur-
veilled for 5 years, was also just reported.23 In this prospective
analysis, the uppermost uromodulin quartile, relative to the
first, was associated with a 55% lower risk of ESRD (hazard
ratio [HR], 0.45; 95% confidence interval [CI], 0.33-0.71),
after comprehensive multivariable adjustment for estimated
glomerular filtration rate (eGFR), proteinuria, prevalent CHD,
all major CVD risk factors, renin-angiotensin-aldosterone
system inhibitor drug use, and serum phosphorus.23
Conflicting Data From Studies of Urinary
Uromodulin Concentrations
Studies of the potential associations between urinary
uromodulin and clinical outcomes in CKD and non-CKD
populations have yielded conflicting results,25-31 perhaps
due, in part, to analytical/methodologic limitations unique
to urinary assays of the glycoprotein.5,32 Youhanna et al32
have demonstrated how storage conditions, centrifugation,
vortexing, pH, electrolytes, and osmolality may adversely af-
fect the stability of uromodulin in urine samples, potentially
altering its polymerization, and causing conformational
changes that modulate antigenic binding sites, and limit uri-
nary assay reproducibility.5 Scherberich et al,5 in contrast,
have reported finding only monomeric uromodulin, free of
any aggregation processes, in serum. Moreover, serum
uromodulin exhibited remarkable stability over weeks, even
at increased temperatures.5 Sejdiu and Torffvit28 reported
that the lowest quartile of urinary uromodulin concentra-
tions was independently associated with a 3.8-fold increased
risk for the development of stage 4 CKD, or ESRD requiring
renal replacement therapy (31 events, pooled), as well as 2.9-
fold greater all-cause (29 events), and 6.3-fold greater (12
events) CVD mortality risks, among n = 131 type I diabetics
followed up for a median of 14 years. However, these lower
urinary uromodulin concentrations did not predict the devel-
opment of stage 4 to 5 CKD (31 events), or overall mortality
(58 events), in their parallel study group of 108 type II
© 2017 Wolters Kluwer Bostom et al 3diabetics surveilled for a median of 4.5 years.28 A rather dif-
ficult to interpret study by Reznichenko et al29 revealed that
the middle tertile of urinary uromodulin excretion (mg/
24 hours) was associated with a greater risk of death-
censored graft failure (n = 42 events), relative to either the
lowest or highest tertiles, after a median follow-up of
5.3 years among 600 chronic stable KTRs. As described by
Zhou et al,25 lower baseline urinary uromodulin levels (as a
continuous variable, or below the median) were indepen-
dently associated with more rapidly declining eGFR, and
a greater extent of biopsy-determined tubular atrophy/
interstitial fibrosis, in n = 185 patients with IgA nephropa-
thy, during a 40 (±2)-month mean observation period. Con-
trastingly, in 2 nested case-control studies of populations
without preexisting CKD, either lower urinary uromodulin
was not associated with CKD incidence,30 or elevated base-
line urine concentrations of the glycoprotein appeared to
predict the development of incident CKD.31 The nested case-
control study of CHD patients reported by Shlipak et al30
found no difference in baseline urinary uromodulin levels be-
tween 100 cases whose eGFR declined to less than 60 mL/
min (median, 44 mg/dL), versus the 94 controls with eGFRs
remaining > 60 ml/min (median, 48 mg/dL). A prior case-
control study by Köttgen et al,31 from the population-based
Framingham Study cohort revealed that among 100 incident
CKD cases whose eGFR declined to less than 60mL/min, rel-
ative to 100 matched controls with follow-up eGFRs greater
than 60 mL/min, median urine uromodulin levels were
0.612 mg/dL, and 0.497 mg/dL, respectively. On the other
hand, 2 large, independent reports of populations free of ini-
tial CKD by Garimella et al26 from the elderly Cardiovas-
cular Health Study (CHS) and Healthy Aging and Body
Composition (Health ABC)27 cohorts, respectively, each dem-
onstrated that lower urinary uromodulin concentrations were
associated with more rapid eGFR decline (n = 192 events in
CHS; n = 91 events in Health ABC), and these associations
were maintained upon adjustment for baseline eGFR, and
urine albumin/creatinine ratio. Lower urine uromodulin con-
centrations were also associated with total mortality (n = 694
events) in CHS,26 after adjustment for eGFR and urinary
albumin/creatinine, but this relationship did not persist in
Health ABC (n = 248 events) when adjusted for these kidney
measures.27 In summary, currently available published data
on urinary uromodulin concentrations as a functional as-
sessment of renal tubular function, and a predictor of adverse
clinical sequelae, are rather equivocal.11,14,16,25-31
Serum Concentrations of Uromodulin as a Predictor of
Clinical Outcomes
The consistent detection of serum uromodulin (as Tamm-
Horsfall protein) was reported already in 1981,10 and nor-
mal serum/plasma ranges established by 1985.11,12 Despite
these developments over 3 decades ago, it is only a recent se-
ries of published reports which have reinvigorated study of
circulating serum/plasma uromodulin concentrations as a
marker of renal tubular function,5,15,17 that may also predict
the development of CVD outcomes,21,22 ESRD,23 and possi-
bly, graft failure among KTRs.24 Two prospective studies
have evaluated the association between serum uromodulin
concentrations and the risk of CVD outcomes and all-
cause mortality in patients undergoing diagnostic coronary
angiography.21,22 Leiherer et al21 studied 529 patientsassessed for known or presumed CHD, and followed for a
mean of 6.5 ± 1.8 years. The lowest tertile of serum
uromodulin, relative to tertiles 2 and 3, pooled, was associated
with a 2.15-fold (HR, 2.15; 95%CI, 1.43-3.22) increased risk
for total mortality (95 events), and a 1.76-fold (HR, 1.76;
95% CI, 1.17-2.67) greater risk for the composite endpoint
of CVD deaths, myocardial infarctions, and strokes (101
events), and these associations persisted after adjustment for
major CVD risk factors and eGFR.21 Delgado et al22 reported
concordant findings from a much larger cohort of patients,
n = 3037, who underwent coronary angiography. During a
median observation period of 9.9 years, there were 818
deaths, including 513 CVD deaths. Relative to the first (refer-
ent) quartile of serum uromodulin concentrations, the fourth
quartile was associated with significantly lower risks for all-
cause (HR, 0.57; 95% CI, 0.45-0.73) and CVD mortality
(HR, 0.48; 95% CI, 0.35-0.66), on multivariable adjustment
for age, sex, uromodulin genotype rs12917707, bodymass in-
dex, diabetes, hypertension, smoking, eGFR, high sensitiv-
ity c reactive protein, N terminal pro b type natriuretic
peptide, and lipid-lowering and antihypertensive/anti-ischemic
drugs.22 Consistent with its putative anti-infectious proper-
ties,4,19,20 and the report by Garimella et al33 that higher
urinary uromodulin levels were associated with a lower inci-
dence of urinary tract infections in an elderly, community-
dwelling cohort, Delgado et al22 also found that the upper
quartile of serum uromodulin concentrations was associated
with a reduced risk (HR, 0.27; 95% CI, 0.12-0.61) for fatal
infections (66 events), after age, sex, and rs129177707 geno-
type adjustment. Lastly, serum uromodulin concentration
shows promise as a diagnostic marker for the group of auto-
somal dominant heritable diseases caused by mutations in
uromodulin coding (UMOD), dubbed Autosomal Dominant
Tubulointerstitial Kidney Disease (ADTKD-UMOD).18,34
These pathogenic mutations typically cause misfolded
uromodulin accumulation within the endoplasmic reticu-
lum of TAL renal tubular cells, resulting in CKD, and its
progression to ESRD.18,34 Satanovskij et al18 have just re-
ported that serum uromodulin concentrations were lower
in all affected patients with a novel missense mutation in
the UMOD gene (457 T > G; Cys153Gly), relative to all pa-
tients of the reference eGFR-matched CKD groups, and
healthy, unaffected family members. These findings are con-
sistentwith the view that while serumuromodulin concentra-
tions are strongly associated with functional renal (especially
tubular) mass, the impact of UMOD variants, per se, on
overall CKD risk, in addition to being age-dependent, is com-
paratively small.34
Uromodulin Quantification in KTRs: Future Directions
Uromodulin/Tamm-Horsfall protein knockout mice are
prone to excess calcium oxalate crystal formation, and the
development of both renal papillary calcification, and ure-
teral stones, emphasizing another plausible role for the glyco-
protein: inhibition of renal/urinary calcification processes.4,35
Furthermore, recurrent human nephrolithiasis is associated
with a greater extent of coronary artery calcification,36
and it is well established that more pronounced vascular cal-
cification occurs in diabetic KTRs.37 The dynamic measure
of serum calcification processes, “T50”/serum calcifica-
tion propensity, has been associated, in cross-section, with
diabetes, among KTRs.38,39 Given the reported association
4 Transplantation DIRECT ■ 2017 www.transplantationdirect.combetween reduced serum uromodulin concentrations and inci-
dent diabetes, or hyperglycemia,40 the potential relationship
between serum uromodulin, and “T50”/serum calcification
propensity,38,39 merits examination in KTR populations. Ini-
tial evidence that increased serum T50 (ie, more prolonged,
meaning less prone to calcification) is associated with lower
rates of mortality and graft failure in KTRs,38,39 underscores
the need to examine these possible interrelationships.
An early 2017 report by Hsu et al,41 detailed how promis-
ing tubular injury biomarkers did not improve prediction of
CKD progression (ie, incident ESRD, or a 50% reduction
in eGFR, pooled; n = 581 events), relative to the combination
of baseline eGFR and urinary albumin/creatinine ratio, among
n = 2466 participants in the Chronic Renal Insufficiency Co-
hort Study. These sobering findings must be born in mind
notwithstanding the small, preliminary studies discussed pre-
viously reporting “independent associations” between lower
serum uromodulin concentrations and nontransplant CKD pro-
gression to ESRD,23 or the occurrence of KTR graft failure.24
Data are required from large, well-characterized,multicen-
ter KTR cohorts assessing the potential relationships between
serum/plasma, or urinary uromodulin concentrations, and
the development of graft failure, as well as CVD outcomes,
and all-cause mortality, among chronic, stable KTRs. For ex-
ample, taking advantage of a powerful, efficient case-cohort
design scheme previously used,42,43 the completed FAVORIT
clinical trial44 cohort might be ideally suited to evaluate these
associations. One of us (A.B.), after establishing the avail-
ability of the relevant case-cohort sample data (ie, baseline
serum and urine specimens, as well as germane nonmissing
covariables) constructed Table 1 to gauge statistical power.
Eighty percent power is estimated (see Table 1) at a 2-tailed
alpha of 0.05 to detect relative risk estimates (RREs) of
1.50 (for CVD), 1.56 (for graft failure) or 1.50 (for death
from any cause), comparing values below the median, to
values equal to or above the median for serum uromodulin
and serum T50, and values at or above the median to those
below the median, for the serum glycemia indices, fruc-
tosamine, and glycated albumin. Adjusting the alpha value
for 5-comparison increases, the RREs detectable with 80%
power to 1.62 (for CVD), 1.72 (for graft failure), or 1.62
(for death from any cause).With the loss of only a few events,TABLE 1.
Power calculations for RREs for a potential FAVORIT trial
case-cohort study based on dichotomizations of < vs ≥ the
median for serum uromodulin and urine uromodulin, and
serum T50; or ≥ vs. < the median for serum fructosamine
and glycated albumin
Outcome matrix
RREs detectable with 80% power
0.05,
2-sided α
0.05/5, corrected for 5
comparisons, 2-sided α
CVDa (309 events/908 KTRs) 1.50 1.62
CVDb (307 events/896 KTRs) 1.50 1.62
Graft failurea (223 events/908 KTRs) 1.56 1.72
Graft failureb (222 events/896 KTRs) 1.58 1.74
All-cause deatha (320 events/908 KTRs) 1.50 1.62
All-cause deathb (315 events/896 KTRs) 1.49 1.61
a Serum.
b Urine.the urine uromodulin RREs are almost identical. Edifying
data such as these would advance our understanding of the
hypothetical utility of serum and uromodulin measurement
in KTRs considerably.
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